1.Progress in non-invasive diagnostic model of hepatic fibrosis.
Bao-En WANG ; Ji-Dong JIA ; Wen-Sheng ZHANG
Chinese Journal of Integrated Traditional and Western Medicine 2006;26(1):5-7
Biomarkers
;
blood
;
Biopsy, Needle
;
utilization
;
Hepatitis C
;
complications
;
Humans
;
Liver
;
pathology
;
Liver Cirrhosis
;
diagnosis
;
pathology
2.Effects of scalp penetration acupuncture on plasma endothelin (ET) and calcitonin related peptide (CGRP) contents in the patient of acute intracerebral hemorrhage.
Chun-Ling BAO ; Hong-Sheng DONG ; Gui-Rong DONG ; En-Li LUO
Chinese Acupuncture & Moxibustion 2005;25(10):717-719
OBJECTIVETo study the mechanism of scalp penetration acupuncture treating acute cerebral hemorrhage (ACH).
METHODSThe treatment group (n = 30) and the control group (n = 30) were treated with the same basic therapy, but scalp penetration acupuncture was added to the treatment group. Changes of plasma ET and CGRP contents were compared.
RESULTSAfter treatment for 14 days, the content of plasma ET in the treatment group was significantly lower than that in the control group (P < 0.01). Moreover, the content of plasma CGRP was significantly higher than that in the control group (P < 0.01).
CONCLUSIONScalp penetration acupuncture is able to improve the prognosis of the patient with ACH by means of regulating the contents of plasma ET and CGRP.
Acupuncture Therapy ; Calcitonin ; Calcitonin Gene-Related Peptide ; Cerebral Hemorrhage ; therapy ; Endothelins ; blood ; Humans ; Scalp
4.The effect of portal hypertension on prognosis in patients with decompensated liver cirrhosis.
Jun-yong ZHANG ; Jing-hua KUAI ; Ji-dong JIA ; Bao-en WANG ; Cheng-yong QIN
Chinese Journal of Hepatology 2009;17(4):263-265
OBJECTIVETo evaluate the effect of portal hypertension on prognosis in patients with decompensated liver cirrhosis.
METHODSThe clinical data of decompensated cirrhosis patients in our hospital, between 2003 and 2006, were retrospected and followed up. Model for end-stage liver disease (MELD) score and Child-Turcotte-Pugh (CTP) classification was calculated using the standard formula. Kaplan-Meier survival analysis was used to compare the mortality in subgroups ranked by the syndromes. Cox proportional hazards regression was used to evaluate the effect of the syndromes on prognosis.
RESULTSA cohort of 322 patients was admitted in this study at the end of the follow-up. The mortality of variceal bleeding, hepatic encephalopathy, a large volume ascites, spontaneous bacterial peritonitis, the type I and type II hepatorenal syndrome was 45.9%, 79.4%, 66.7%, 100%, 100% and 84.6% respectively. On the whole, the occurrence of all the syndromes was correlated with CTP classification and MELD score. Kaplan-Meier survival analysis showed that all of these syndromes, except for low to medium volume of ascites, significantly affected the survival rate (P<0.01). In Cox regression analysis, all the syndromes were the independent predictors of prognosis, the regression coefficient values of hepatic encephalopathy, spontaneous bacterial peritonitis, type I and type II hepatorenal syndrome, variceal bleeding and ascites were 0.973, 0.928, 0.935, 0.866, 0.464 and 0.369 respectively.
CONCLUSIONSThe portal hypertensive syndromes have significant effect on the prognosis of the patients with decompensated cirrhosis, hepatic encephalopathy is the worst one.
Adult ; Aged ; Esophageal and Gastric Varices ; epidemiology ; etiology ; Female ; Follow-Up Studies ; Gastrointestinal Hemorrhage ; epidemiology ; etiology ; Hepatic Encephalopathy ; epidemiology ; etiology ; Hepatorenal Syndrome ; epidemiology ; etiology ; Humans ; Hypertension, Portal ; complications ; epidemiology ; Liver Cirrhosis ; complications ; mortality ; pathology ; Male ; Middle Aged ; Models, Statistical ; Predictive Value of Tests ; Prognosis ; Severity of Illness Index ; Survival Analysis
7.Effects of herbal compound 861 on hepatic stellate cell expressing endothelin-1 protein and mRNA.
Hui-guo DING ; Shu-zhen TANG ; Bao-en WANG ; Ji-dong JIA ; Chun-hui ZHAO
Chinese Journal of Hepatology 2003;11(5):308-308
Animals
;
Cells, Cultured
;
Drugs, Chinese Herbal
;
pharmacology
;
Endothelin-1
;
biosynthesis
;
genetics
;
Hepatocytes
;
metabolism
;
Liver
;
cytology
;
metabolism
;
Liver Cirrhosis
;
prevention & control
;
RNA, Messenger
;
biosynthesis
;
genetics
;
Rats
;
Rats, Sprague-Dawley
;
Simian virus 40
;
genetics
;
Transfection
8.Serum sodium concentration profile for cirrhotic patients and its effect on the prognostic value of the MELD score.
Jun-Yong ZHANG ; Cheng-Yong QIN ; Ji-Dong JIA ; Bao-En WANG
Chinese Journal of Hepatology 2012;20(2):108-111
To analyze the characteristics of serum sodium in decompensated cirrhosis and evaluate the prognostic ability of the model for end-stage liver disease (MELD) in Na-containing models. Patients diagnosed with decompensated cirrhosis at our hospital were enrolled for study between June 2005 and October 2010. Patients were classified among three groups, according to serum sodium concentration: less than 125 mmol/L, 125 to 135 mmol/L, and more than 135 mmol/L. Mortality rates among the three groups were compared by Kaplan-Meier survival analysis. In addition, the different serum sodium concentrations were analyzed for correlations between Child-Pugh score and complication incidence rates of portal hypertension. The area under the receiver operating characteristic (ROC) curve (AUC) was used to compare the predictive abilities of MELD, MELD-Na, and the integrated (i) MELD scores for 3-month, 6-month and 1-year mortalities. A total of 467 patients were analyzed, and 50.54% had hyponatremia ( less than 135 mmol/L). Sodium concentration was correlated with mortality, and Kaplan-Meier survival analysis indicated that mortality was significantly higher in each subgroup with lower sodium concentration (all, P = 0.000). Likewise, sodium concentration decreased in conjunction with increased severity of decompensation, as classified by Child-Pugh scoring (sodium: A more than B more than C; mortality: A less than B less than C). With the exception of digestive tract bleeding, complication incidence rates of hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome increased when sodium concentration decreased. For predicting 3-month mortality, the AUC scores of MELD were not significantly different from the MELD-Na and iMELD scores (P more than 0.05). For predicting 6-month and 1-year mortality, the AUC scores of MELD-Na and iMELD were significantly higher than those of MELD (P less than 0.05). Hyponatremia is correlated with mortality and complications in decompensated cirrhosis patients. Incorporation of Na into the MELD may enhance it's prognostic ability.
Adult
;
Aged
;
End Stage Liver Disease
;
Female
;
Humans
;
Liver Cirrhosis
;
blood
;
Liver Failure
;
diagnosis
;
Male
;
Middle Aged
;
Predictive Value of Tests
;
Prognosis
;
Serum
;
chemistry
;
Severity of Illness Index
;
Sodium
;
blood
9.The effect of angiotensin II type 1 receptor blocker valsartan in preventing hepatic fibrosis induced by dimethylnitrosamine in rats.
Feng-jun SHEN ; Yue-ke ZHU ; Ji-dong JIA ; Hong MA ; Bao-en WANG
Chinese Journal of Hepatology 2004;12(10):605-608
OBJECTIVETo observe the effects of angiotensin II type 1 receptor blocker valsartan in preventing hepatic fibrosis induced by dimethylnitrosamine in rats.
METHODSExcept rats in the control group, all were given intraperitoneal injections of 1% dimethylnitrosamine (DMN 1 ml/kg, two or three consecutive days/a week for 6 weeks). From the first day of the intraperitoneal injection, rats in treatment groups were given valsartan for 8 weeks by gastric gavage. Liver tissue and blood samples of all rats were examined at 56 days (8 weeks). AngII levels were determined by radioimmunoassay. Hepatic mRNA levels of Collagen type I (Col I) and tissue inhibitor of metalloproteinase1 (TIMP1) were evaluated by reverse-transcription polymerase chain reaction (RT-PCR).
RESULTSValsartan significantly attenuated the degree of liver fibrosis and decreased the hepatic AngII content compared with DMN treated rats (P<0.01). mRNA levels of Col I and TIMP1 were upregulated in DMN treated rats compared with normal rats. Valsartan downregulated the elevation of Col I and TIMP1 mRNA levels (P<0.01).
CONCLUSIONHepatic AngII content of the model group was increased, the local tissue RAS was activated in DMN induced liver fibrosis. Valsartan can retard the progression of hepatic fibrosis and may provide an effective new strategy for anti-liver fibrosis therapy.
Angiotensin II Type 1 Receptor Blockers ; pharmacology ; therapeutic use ; Animals ; Dimethylnitrosamine ; Female ; Liver Cirrhosis, Experimental ; chemically induced ; prevention & control ; Male ; Random Allocation ; Rats ; Rats, Wistar ; Tetrazoles ; pharmacology ; therapeutic use ; Valine ; analogs & derivatives ; pharmacology ; therapeutic use ; Valsartan
10.The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial.
Shan-shan YIN ; Bao-en WANG ; Tai-ling WANG ; Ji-dong JIA ; Lin-xue QIAN
Chinese Journal of Hepatology 2004;12(8):467-470
OBJECTIVESTo further assess the clinical antifibrotic efficacy of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis using a randomized, double blind, and placebo controlled clinical trial.
METHODSTotal 136 patients with HBV-related fibrosis and early cirrhosis were allocated randomly into Cpd 861 treatment group and placebo group for 24 weeks treatment. Serum fibrosis markers including hyaluronic acid (HA), IV collagen (IV-C), amino terminal propeptide of type III procollagen (PIIIP), and laminin (LN) and serum MMP1, 2, 9, TIMP1, 2 level were determined before and after 24 weeks treatment. Liver biopsies before and after 24 weeks of treatment were assessed according to modified Scheuer and Chevallier's scoring system.
RESULTSTotal 52 patients in Cpd 861 treatment group and 50 patients in placebo-controlled group completed the 6 months. ALT level decreased from 68.2 U/L+/-68.6 U/L to 45.9 U/L+/-26.1 U/L, AST level decreased from 60.4 U/L+/-62.6 U/L to 46.7 U/L+/-39.0 U/L (P < 0.05) after 24 weeks treatment, whereas there was no significant change in placebo group (ALT: 65.3 U/L+/-48.3 U/L to 85.4 U/L+/-115.5 U/L; AST: 60.4 U/L+/-44.6 U/L to 77.6 U/L+/-89.6 U/L, P > 0.05). Serum fibrosis markers, including HA, IV-C, PIIIP, and LN were decreased after treatment, but there is no statistically significant compared with placebo group. Compared with placebo group, serum TIMP1 and MMP9 level decreased significantly (TIMP1 172.0 ng/ml+/-79.6 ng/ml vs 133.5 ng/ml+/-66.8 ng/ml; MMP9 116.1 ng/ml+/-88.2 ng/ml vs 80.4 ng/ml+/-79.0 ng/ml), and the ratio of TIMP1/MMP1 (48.3+/-96.3 vs 19.9+/-28.0) were also decreased after 861 treatment. In patients treated with Cpd 861, hepatic inflammatory score (from 14.0+/-6.0 to 10.2+/-6.1), fibrosis score (from 11.9+/-6.5 to 8.2+/-4.5), and relative content of collagen (from 18.9%+/-9.5% to 14.9%+/-8.4%) decreased significantly. In contrast, there was no significant change in placebo group. The reversal (fibrosis score decrease > or = 2) rate of fibrosis in Cpd 861 group was 38.9% in S2, 53.3% in S3 (precirrhotic) and 78.6% in S4 (cirrhosis), significantly higher than those in placebo group (14.3%, 25.0%, and 41.7%, respectively). The overall reversal rate was 52.0% in Cpd 861 group, and 20.0% in placebo group (P < 0.05). No serious adverse effects were observed during Cpd 861 treatment.
CONCLUSIONLiver fibrosis and early cirrhosis due to HBV infection in man could be definitely reversed by herbal remedy Cpd 861.
Adolescent ; Adult ; Aged ; Collagen Type IV ; blood ; Double-Blind Method ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Hepatitis B, Chronic ; complications ; drug therapy ; Humans ; Hyaluronic Acid ; blood ; Liver ; pathology ; Liver Cirrhosis ; blood ; drug therapy ; etiology ; Liver Function Tests ; Male ; Middle Aged ; Phytotherapy